Protein Hydrolysate of Green Peas Bromelain Attenuates Kidney Fibrosis in Cisplatin-Induced Nephrotoxicity Rats: Emphasis on Anti-Inflammatory Activities
Massive tubule fibrosis is a histopathology hallmark of chronic renal failure (CRF). The previous study of protein hydrolysate of green pea (Pisum sativum) bromelain (PHGPB) showed promising results as an antifibrosis in glucose-induced renal mesangial culture cells, by decreasing their TGF-β levels. In this experiment the anti-inflammatory, anti-fibrotic effect of PHGPB in Cisplatin-induced chronic renal failure (CRF) rats was measured. The purpose of this study is to evaluate the anti-inflammatory and antifibrosis effect of PHGPB in Cisplatin-induced chronic renal failure rats. Five groups consisted of five rats: negative control, Cisplatin control, and three groups of Cisplatin+PHGPB (dose of 100, 200, and 400 mg/kg BW/day) treated for 56 days. The examined parameters are Beta-2-microglobulin (β2MG), hs-CRP, histopathological observations of Masson's trichrome stain, and IHC. The level of β2MG and hs-CRP in the Cisplatin+PHGPB group lowered and was highly different from Cisplatin control (p<0.05) depending on doses. In histopathology, the Cisplatin+PHGPB 400 mg/kg BW group showed less fibrosis and no significant difference with the negative control in Masson trichome staining. While in IHC histopathology, PHGPB treatment slightly ameliorated TGF-β expression and intensity of TGF-β values convincingly. In conclusion, PHGPB can relieve kidney fibrosis in cisplatin-induced nephrotoxicity rats: Emphasis on anti-inflammatory activities.
Copyright (c) 2023 Meilinah Hidayat; Retno Pangastuti, Sijani Prahastuti; Khomaini Hasan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
HAYATI J Biosci article's license is CC-BY-NC. This license lets others distribute, remix, tweak, and build upon author's work, as long as they credit the original creation.
Authors who submit and publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal/publisher non exclusive publishing rights with the work simultaneously licensed under a https://creativecommons.org/
licenses/by-nc/4.0/Attributi on — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- Authors can still use their work commercially
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).